Dose-escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase Ia/Ib results and immune modulation insights.

Signal Transduct Target Ther · 2025 · PMC12304480 · PMID 40721581

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

an increasing trendno p-value reported

Interestingly, the proportion of this subpopulation varied across different patients: a decreasing trend was observed in Cohort I, whereas an increasing trend was observed in some patients from Cohorts II, III, and IV (Supplementary Fig. 2b ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.